ID Biomedical

IDB-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about IDB-T

Signal
Opinion
Expert
HOLD
HOLD
September 20, 2005
GlaxcoSmithKline (GSK-N) is taking the company over. Speculation is that someone else will come in with a better offer. Can't see much risk in holding on to your shares.
ID Biomedical (IDB-T)
September 20, 2005
GlaxcoSmithKline (GSK-N) is taking the company over. Speculation is that someone else will come in with a better offer. Can't see much risk in holding on to your shares.
Norman Levine
Managing Director, Portfolio Management Corp
Price
$34.900
Owned
Unknown
BUY
BUY
May 9, 2005
Have a large vaccine contract in the US. Should have a large increase in earnings and the stock should have a lot of upside.
Have a large vaccine contract in the US. Should have a large increase in earnings and the stock should have a lot of upside.
Jean-Francois Tardif
Senior Portfolio Manager, Sprott Asset Management
Price
$21.500
Owned
Yes
DON'T BUY
DON'T BUY
December 3, 2004
Biotech stocks are very risky. This one has done very well on the flu vaccine problem in the US. A low margin business. Very expensive.
ID Biomedical (IDB-T)
December 3, 2004
Biotech stocks are very risky. This one has done very well on the flu vaccine problem in the US. A low margin business. Very expensive.
Jean-Francois Tardif
Senior Portfolio Manager, Sprott Asset Management
Price
$20.050
Owned
No
BUY
BUY
August 23, 2004
The pharmaceutical sector has been torn apart. This company that has done a very good job in managing and developing some products.
ID Biomedical (IDB-T)
August 23, 2004
The pharmaceutical sector has been torn apart. This company that has done a very good job in managing and developing some products.
Robert Floyd
President, R A Floyd Management
Price
$14.640
Owned
Yes
BUY WEAKNESS
BUY WEAKNESS
September 22, 2003
Likes the story. Has had a pretty good run, but has more room to go. Very strong news out of the company. Some trial results still to come out in the next little while.
ID Biomedical (IDB-T)
September 22, 2003
Likes the story. Has had a pretty good run, but has more room to go. Very strong news out of the company. Some trial results still to come out in the next little while.
Robert Floyd
President, R A Floyd Management
Price
$25.470
Owned
Unknown
BUY WEAKNESS
BUY WEAKNESS
July 29, 2003
Developing a flu vaccine. Well cashed up. Would buy it, but at a lower level.
ID Biomedical (IDB-T)
July 29, 2003
Developing a flu vaccine. Well cashed up. Would buy it, but at a lower level.
Peter Hodson
CEO & Head of Research, 5i Research Inc.
Price
$17.540
Owned
No
BUY
BUY
March 3, 2003
Good product. In final phases of testing.
ID Biomedical (IDB-T)
March 3, 2003
Good product. In final phases of testing.
Robert Floyd
President, R A Floyd Management
Price
$8.160
Owned
Unknown
WEAK BUY
WEAK BUY
February 4, 2003
Very volatile. Well managed and has a lot of cash.
ID Biomedical (IDB-T)
February 4, 2003
Very volatile. Well managed and has a lot of cash.
Peter Hodson
CEO & Head of Research, 5i Research Inc.
Price
$10.060
Owned
Unknown
BUY
BUY
January 15, 2003
Still has substantial upside. Into some interesting products.
ID Biomedical (IDB-T)
January 15, 2003
Still has substantial upside. Into some interesting products.
Robert Floyd
President, R A Floyd Management
Price
$11.450
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
April 5, 2002
(Was a top pick on Dec 21 up 50%) Can still go higher.
ID Biomedical (IDB-T)
April 5, 2002
(Was a top pick on Dec 21 up 50%) Can still go higher.
Robert Floyd
President, R A Floyd Management
Price
$9.610
Owned
Unknown
TOP PICK
TOP PICK
December 21, 2001
Well capitalized. Strong management.
ID Biomedical (IDB-T)
December 21, 2001
Well capitalized. Strong management.
Robert Floyd
President, R A Floyd Management
Price
$6.640
Owned
Unknown
TOP PICK
TOP PICK
Robert Floyd
President, R A Floyd Management
Price
$5.150
Owned
Unknown
TOP PICK
TOP PICK
June 14, 2001
Strong cash position. Good mngmnt. Good outlook.
ID Biomedical (IDB-T)
June 14, 2001
Strong cash position. Good mngmnt. Good outlook.
Robert Floyd
President, R A Floyd Management
Price
$6.400
Owned
Unknown
TOP PICK
TOP PICK
May 14, 2001
Well capitalized. Good product line.
Well capitalized. Good product line.
Robert Floyd
President, R A Floyd Management
Price
$5.950
Owned
Unknown
TOP PICK
TOP PICK
March 28, 2001
New acquisition is a good fit. Strong cash positions.
ID Biomedical (IDB-T)
March 28, 2001
New acquisition is a good fit. Strong cash positions.
Robert Floyd
President, R A Floyd Management
Price
$4.810
Owned
Unknown
BUY
BUY
March 6, 2001
Likes. Has dropped, but some exciting things coming up on it.
ID Biomedical (IDB-T)
March 6, 2001
Likes. Has dropped, but some exciting things coming up on it.
Pier Donnini
Head of Institutional Securities, Yorkton Securities
Price
$6.700
Owned
Unknown
STRONG BUY
STRONG BUY
January 31, 2001
Great company and at a good price
ID Biomedical (IDB-T)
January 31, 2001
Great company and at a good price
Malvin Spooner
Chairman and Chief Executive Officer, Mavrix Fund Management
Price
$8.000
Owned
Unknown
BUY
BUY
November 1, 2000
Well capitalized. Applications in stage 3
ID Biomedical (IDB-T)
November 1, 2000
Well capitalized. Applications in stage 3
Robert Floyd
President, R A Floyd Management
Price
$9.000
Owned
Unknown
TOP PICK
TOP PICK
October 24, 2000
Their software is needed by pharmaceuticals working in genomics
ID Biomedical (IDB-T)
October 24, 2000
Their software is needed by pharmaceuticals working in genomics
Malvin Spooner
Chairman and Chief Executive Officer, Mavrix Fund Management
Price
$10.000
Owned
Unknown
Showing 1 to 19 of 19 entries
  • «
  • 1
  • »